Table 1.
Results of randomized clinical trials evaluating neoadjuvant chemotherapy for muscle-invasive bladder cancer
| Study | N | Regimen | Comparator | pCR | OS |
|---|---|---|---|---|---|
| EORTC/MRC36 | 976 | CMV (3 cycles) followed by cystectomy or RT (n = 491) | Cystectomy or RT (n = 485) | 33% | 5.5% in favor of CMV |
| INT 0080/SWOG 871038 | 317 | M-VAC (3 cycles) followed by cystectomy (n = 154) | Cystectomy (n = 153) | 38% | Trend in benefit with M-VAC (P = 0.06) |
| Nordic39 | 325 | CA (2 cycles) followed by cystectomy or RT (n = 151) | Cystectomy or RT (n = 160) | NR | No difference |
| Nordic 237 | 317 | CM (3 cycles) followed by cystectomy (n = 155) | Cystectomy (n = 154) | 26.4% | No difference |
| Italy (GISTV)40 | 171 | M-VEC (3 cycles) followed by cystectomy (n = 82) | Cystectomy (n = 71) | 28% | No difference |
Abbreviations: pCR, pathologic complete response; OS, overall survival; CMV, cisplatin + methotrexate + vinblastine; M-VAC, methotrexate + vinblastine + adriamycin + cisplatin; NR, not reported; CA, cisplatin + adriamycin; CM, cisplatin + methotrexate; M-VEC, methotrexate + vinblastine + epirubicin + cisplatin; SWOG, South West Oncology Group; RT, radiotherapy.